71 related articles for article (PubMed ID: 22064107)
21. Determination of optimum periods between onset of suspected acute myocarditis and ¹⁸F-fluorodeoxyglucose positron emission tomography in the diagnosis of inflammatory left ventricular myocardium.
Ozawa K; Funabashi N; Daimon M; Takaoka H; Takano H; Uehara M; Kobayashi Y
Int J Cardiol; 2013 Nov; 169(3):196-200. PubMed ID: 24075573
[TBL] [Abstract][Full Text] [Related]
22. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG?
Roels S; Slagmolen P; Nuyts J; Lee JA; Loeckx D; Maes F; Stroobants S; Penninckx F; Haustermans K
Acta Oncol; 2008; 47(7):1237-48. PubMed ID: 18654902
[TBL] [Abstract][Full Text] [Related]
23. Animal-specific positioning molds for registration of repeat imaging studies: comparative microPET imaging of F18-labeled fluoro-deoxyglucose and fluoro-misonidazole in rodent tumors.
Zanzonico P; Campa J; Polycarpe-Holman D; Forster G; Finn R; Larson S; Humm J; Ling C
Nucl Med Biol; 2006 Jan; 33(1):65-70. PubMed ID: 16459260
[TBL] [Abstract][Full Text] [Related]
24. Two or four hour [¹⁸F]FMISO-PET in HNSCC. When is the contrast best?
Abolmaali N; Haase R; Koch A; Zips D; Steinbach J; Baumann M; Kotzerke J; Zöphel K
Nuklearmedizin; 2011; 50(1):22-7. PubMed ID: 21165537
[TBL] [Abstract][Full Text] [Related]
25. Thyroid incidentaloma identified by ¹⁸F-fluorodeoxyglucose positron emission tomography with CT (FDG-PET/CT): clinical and pathological relevance.
Pagano L; Samà MT; Morani F; Prodam F; Rudoni M; Boldorini R; Valente G; Marzullo P; Baldelli R; Appetecchia M; Isidoro C; Aimaretti G
Clin Endocrinol (Oxf); 2011 Oct; 75(4):528-34. PubMed ID: 21575027
[TBL] [Abstract][Full Text] [Related]
26. Optimization of the reference region method for dual pharmacokinetic modeling using Gd-DTPA/MRI and (18) F-FDG/PET.
Poulin É; Lebel R; Croteau É; Blanchette M; Tremblay L; Lecomte R; Bentourkia M; Lepage M
Magn Reson Med; 2015 Feb; 73(2):740-8. PubMed ID: 24604379
[TBL] [Abstract][Full Text] [Related]
27. [Value of 18F-FDG and 11C-MET PET-CT in differentiation of brain ringlike-enhanced neoplastic and non-neoplastic lesions on MRI imaging].
Cai L; Gao S; Li DC; Li YS; Chen QS; Xing XL
Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):134-8. PubMed ID: 19538892
[TBL] [Abstract][Full Text] [Related]
28. The role of (18) F-fluorodeoxyglucose-positron emission tomography in the assessment of disease activity in patients with takayasu arteritis.
Lee KH; Cho A; Choi YJ; Lee SW; Ha YJ; Jung SJ; Park MC; Lee JD; Lee SK; Park YB
Arthritis Rheum; 2012 Mar; 64(3):866-75. PubMed ID: 21989701
[TBL] [Abstract][Full Text] [Related]
29. Characterization of different osteosarcoma phenotypes by PET imaging in preclinical animal models.
Campanile C; Arlt MJ; Krämer SD; Honer M; Gvozdenovic A; Brennecke P; Fischer CR; Sabile AA; Müller A; Ametamey SM; Born W; Schibli R; Fuchs B
J Nucl Med; 2013 Aug; 54(8):1362-8. PubMed ID: 23801674
[TBL] [Abstract][Full Text] [Related]
30. In vivo PET/CT in a human glioblastoma chicken chorioallantoic membrane model: a new tool for oncology and radiotracer development.
Warnock G; Turtoi A; Blomme A; Bretin F; Bahri MA; Lemaire C; Libert LC; Seret AE; Luxen A; Castronovo V; Plenevaux AR
J Nucl Med; 2013 Oct; 54(10):1782-8. PubMed ID: 23970367
[TBL] [Abstract][Full Text] [Related]
31. Characterization of biological features of a rat F98 GBM model: a PET-MRI study with [18F]FAZA and [18F]FDG.
Belloli S; Brioschi A; Politi LS; Ronchetti F; Calderoni S; Raccagni I; Pagani A; Monterisi C; Zenga F; Zara G; Fazio F; Mauro A; Moresco RM
Nucl Med Biol; 2013 Aug; 40(6):831-40. PubMed ID: 23915802
[TBL] [Abstract][Full Text] [Related]
32. Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer.
Huang T; Civelek AC; Li J; Jiang H; Ng CK; Postel GC; Shen B; Li XF
J Nucl Med; 2012 Aug; 53(8):1262-8. PubMed ID: 22717978
[TBL] [Abstract][Full Text] [Related]
33. PET radiopharmaceuticals in radiation treatment planning - synthesis and biological characteristics.
Haubner R
Radiother Oncol; 2010 Sep; 96(3):280-7. PubMed ID: 20724013
[TBL] [Abstract][Full Text] [Related]
34. (18)F-fluorodeoxyglucose positron emission tomography to assess response after radiation therapy in anaplastic thyroid cancer.
Levy A; Leboulleux S; Lepoutre-Lussey C; Baudin E; Ghuzlan AA; Hartl D; Deutsch E; Deandreis D; Lumbroso J; Tao Y; Schlumberger M; Blanchard P
Oral Oncol; 2015 Apr; 51(4):370-5. PubMed ID: 25595614
[TBL] [Abstract][Full Text] [Related]
35. Does adding FDG-PET to MRI improve the differentiation between primary cerebral lymphoma and glioblastoma? Observer performance study.
Makino K; Hirai T; Nakamura H; Murakami R; Kitajima M; Shigematsu Y; Nakashima R; Shiraishi S; Uetani H; Iwashita K; Akter M; Yamashita Y; Kuratsu J
Ann Nucl Med; 2011 Jul; 25(6):432-8. PubMed ID: 21404136
[TBL] [Abstract][Full Text] [Related]
36. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
Wu ZJ; Zhang YX; Wei H; Jia Q
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the antitumor effects of rilotumumab by PET imaging in a U-87 MG mouse xenograft model.
Rex K; Lewis XZ; Gobalakrishnan S; Glaus C; Silva MD; Radinsky R; Burgess TL; Gambhir SS; Coxon A
Nucl Med Biol; 2013 May; 40(4):458-63. PubMed ID: 23454250
[TBL] [Abstract][Full Text] [Related]
38. Pituitary adenomas can appear as hypermetabolic lesions in (18) F-FDG PET imaging.
Ryu SI; Tafti BA; Skirboll SL
J Neuroimaging; 2010 Oct; 20(4):393-6. PubMed ID: 19453834
[TBL] [Abstract][Full Text] [Related]
39. Predictors of initial 18F-fluorodeoxyglucose-positron emission tomography indication among patients with colorectal cancer.
Zafar HM; Kramer S; Bonaccorsi D; Langlotz CP; Armstrong K
Nucl Med Commun; 2012 Jul; 33(7):739-46. PubMed ID: 22531828
[TBL] [Abstract][Full Text] [Related]
40. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
